<DOC>
	<DOCNO>NCT00027560</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , melphalan fludarabine , monoclonal antibody , alemtuzumab , donor bone marrow peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine transplant may stop happen . PURPOSE : This phase II trial study well fludarabine , melphalan , alemtuzumab , peripheral stem cell transplant work treat patient hematologic cancer .</brief_summary>
	<brief_title>Melphalan , Fludarabine , Alemtuzumab Followed Peripheral Stem Cell Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Overall survival-12 month Overall survival-24 month Acute Graft-versus-Host Disease Matched Related patients-up 4 month post transplant Acute Graft-versus-Host Disease Unrelated Mismatched relate patients- 4 month post transplant Chronic Graft-versus-Host Disease Matched Related patients- 2 year post transplant Chronic Graft-versus-host disease Unrelated Mismatched relate patients- 2 year post transplant - OUTLINE : Patients stratify accord donor type ( HLA-matched relate v HLA-matched unrelated , single HLA-allele disparate relate , unmatched ) ( HLA-mismatched relate match unrelated donor stratum close accrual 1/11/06 ) . Patients receive nonmyeloablative regimen comprise alemtuzumab IV 8 hour day -8 -5 , fludarabine IV 30 minute day -8 -4 , melphalan IV 30 minute day -3 -2 . Allogeneic peripheral blood stem cell bone marrow infuse day 0 . Patients receive graft-versus host disease prophylaxis comprise cyclosporine IV every 12 hour begin day -1 continue orally tolerate day 100 . Patients follow every 6 week 6 month , every 3 month 6 month , every 3-6 month 1 year , annually thereafter clinically indicate . PROJECTED ACCRUAL : A maximum 50 patient ( 25 HLA-matched related 25 HLA-mismatched relate matched unrelated ) accrue study within 2 year ( HLA-mismatched relate match unrelated donor stratum close accrual 1/11/06 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : Disease criterion : This trial primarily design : 1 ) patient relapse primary refractory nonHodgkin 's lymphoma , 2 ) chemosensitive relapse refractory acute chronic lymphocytic leukemia , 3 ) relapse primary refractory Hodgkin 's Disease , advance ( DurieSalmon stage II III ) multiple myeloma , advance Waldenstrom macroglobulinemia , , virtue advance age , intensity prior radiation and/or chemotherapy , history prior toxicity associate chemo/radiotherapy exist organ dysfunction , would undue risk regimen associate mortality transplant accord protocol involve myeloablative conditioning regimen . Patients aggressive NHL histology must chemo/radiosensitive disease , nonprogressive disease , stable disease therapy , ineligible autologous HSC transplant disease marrow . Patients chronic myeloid leukemia high risk form acute myelogenous leukemia myelodysplastic syndrome also eligible absence alternative active high priority allogeneic transplant protocol eligible . Age criterion : Patients may 70 year age . There low age threshold . Patients age 70 may also participate , evaluation approval BMT Service attending . Absence active uncontrolled bacterial , viral , fungal infection would contraindicate use myelosuppressive chemotherapy . Patients must healthy HLAcompatible donor , either match single HLA allele disparate relate donor similarly compatible unrelated donor recruit National Marrow Donor Program . Related donor must willing participate research subject willing receive GCSF mobilize PBPC undergo leukapheresis donate PBSC . Unrelated donor identify NMDP may elect donate either PBSC treatment GCSF , bone marrow . These unrelated donor provide inform consent PBSC bone marrow donation obtain qualified donor center participate NMDP . Each patient must willing participate research subject must sign informed consent form discussion nature risk study prior enter protocol . Parents legal guardian patient minor sign consent form patient discussion nature risk study . EXCLUSION CRITERIA : Female patient pregnant lactate . Active uncontrolled viral ( include HIV1 ) , bacterial fungal infection . Severe renal insufficiency ( creatinine &gt; 2.0 creatinine clearance &lt; 30mL/minute ) Severe hepatic dysfunction , define : total bilirubin great 2.5 mg/dL AST ALT &gt; 3xnl , unless liver involved disease . Severe cardiac insufficiency , define rest leave ventricular ejection le 30 % measure echocardiography radionuclide cardiac angiography . Patients cardiac medication congestive heart failure eligible , long LVEF great 30 % medication . Severe pulmonary insufficiency , define adjust diffuse capacity le 40 % predict value . Karnofsky Lansky score &lt; 40 %</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>